Xuanzhu Biopharmaceutical Co., Ltd. Shares Added to Hong Kong Stock Connect Lists

Key Update: Expanded Access for Mainland Investors, Potential for Enhanced Liquidity and Shareholder Base

Xuanzhu Biopharmaceutical Co., Ltd. (“Xuanzhu Biopharm”, Stock Code: 2575) has announced a significant development for its shareholders and potential investors: The company’s shares have been officially included in the list of eligible stocks for trading under both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect effective 9 March 2026.

Highlights of the Announcement

• Inclusion in Stock Connect: Xuanzhu Biopharm’s shares will be available to mainland Chinese investors through the Stock Connect program, substantially broadening the investor base. The inclusion follows the official announcements by both the Shanghai Stock Exchange and Shenzhen Stock Exchange on 6 March 2026.
• Effective Date: The company’s shares become eligible for Stock Connect trading from 9 March 2026.
• Anticipated Impact: The Board expects that this development will help expand the Company’s shareholder base and enhance the liquidity of Xuanzhu Biopharm’s shares. Increased market access and liquidity are often viewed as positive factors for share price performance.

Why This Matters to Shareholders

• Price-Sensitive and Potentially Value-Enhancing: Inclusion in the Stock Connect programs is generally seen as a price-sensitive event. It can attract new institutional and retail investors from mainland China, potentially increasing trading volumes and supporting share prices.
• Market Visibility: The expansion into the Shanghai and Shenzhen Stock Connect lists may raise the company’s profile among investors and analysts, further supporting interest in the shares.
• Liquidity: Higher trading liquidity can benefit existing shareholders by narrowing bid-ask spreads and allowing easier entry and exit from positions.

About Xuanzhu Biopharmaceutical Co., Ltd.

Xuanzhu Biopharm is an innovative pharmaceutical company headquartered in China with a global vision. The company focuses on major disease areas including digestion, oncology, and non-alcoholic steatohepatitis. Xuanzhu is committed to the research and development (R&D), production, and commercialization of Class 1 drugs with proprietary intellectual property rights.

• R&D Strength: Xuanzhu boasts a top-tier R&D team with extensive experience in new drug development.
• Dual R&D Platforms: The company operates two platforms: small molecule chemistry and large molecule biopharmaceuticals, enabling innovation across a broad product pipeline.
• Product Pipeline: The pipeline covers small molecules, large molecules, antibody-drug conjugates (ADC), and other advanced therapeutics.
• Strategic Focus: Xuanzhu is dedicated to addressing significant unmet clinical needs and aims to become a leading innovative pharmaceutical enterprise with comprehensive R&D, production, and sales capabilities.

Leadership and Governance

The board is chaired by Ms. Xu Yanjun, who also serves as executive Director. The board includes a mix of executive, non-executive, and independent non-executive directors, indicating a robust corporate governance structure.

Potential Implications for Investors

• The expansion of the shareholder base and increased liquidity may drive further institutional interest and support the share price.
• Existing shareholders should monitor trading volumes and price movements following the inclusion date, as Stock Connect eligibility often leads to increased market activity.
• The company’s continued commitment to R&D and innovation, coupled with enhanced market access, positions Xuanzhu Biopharm for potential growth and value creation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult professional advisors before making any investment decisions. Past performance is not indicative of future results. The author and publisher accept no liability for any actions taken based on this article.

View XUANZHUBIO-B Historical chart here